STAAR Surgical Co

Staar Surgical (NSDQ:STAA) shares ticked up today on second-quarter results that topped the consensus forecast.

The Lake Forest, Calif.-based implantable lens maker posted profits of $8.6 million, or 17¢ per share, on sales of $62.4 million for the three months ended July 2, 2021, for a massive bottom-line from over $1 million in the red this time last year on sales growth of 77.2%.

Adjusted to exclude one-time items, earnings per share were 27¢, 3¢ ahead of Wall Street, where analysts were looking for sales of $52.6 million.

“STAAR’s second-quarter results reflect the accelerating sales momentum and significant opportunity for our vision correction lenses,” Staar Surgical president & CEO Caren Mason said in a news release. “Global ICL unit growth increased 79% over the prior-year quarter and we achieved positive sales and unit growth in all of our major markets. Asia, Europe, and the U.S. led our outperformance during the quarter. The Mi…

Staar Surgical (NSDQ:STAA) yesterday posted first-quarter results that beat the overall consensus on Wall Street.

The Lake Forest, Calif.-based company reported profits of $4.99 million, or 10¢ per share, on sales of $50.75 million for the three months ended April 2, for a sales growth of 44.24% compared with Q1 2020.

Adjusted to exclude one-time items, earnings per share were 20¢, 17¢ ahead of The Street, where analysts were looking for sales of $44.26 million.

“Every major market delivered outstanding performance during the first quarter of 2021 providing a record-breaking quarterly achievement of net sales of $50.8 million. First-quarter ICL sales of $46.5 million and unit growth of 54% continued the increasing momentum from second half 2020 results and represents a return to the strong demand for ICL lenses we experienced in January 2020 prior to the pandemic taking hold,” president and CEO Caren Mason said in a news release. “ICL unit growth in the …

Staar Surgical (NSDQ:STAA) posted fourth-quarter results yesterday that beat the consensus forecast on Wall Street.

The Lake Forest, Calif.-based company reported profits of $3.3 million, or 7¢ per share, on sales of $46 million for the three months ended Jan. 1, 2021, for a bottom-line loss of -47.8% sales growth of 18.3% compared with Q4 2019.

Adjusted to exclude one-time items, earnings per share were 14¢, 4¢ ahead of The Street, where analysts were looking for sales of $44.5 million.

“Our 2020 performance reflects the continued momentum behind STAAR’s commercial growth and product innovation. Consequently, we achieved strong fourth-quarter results and met our original sales targets for the second half of 2020, despite the unprecedented global pandemic. Our momentum has continued into the first weeks of 2021,” president and CEO Caren Mason said in a news release.

Staar Surgical did not provide a financial outlook for 2021.

Shares in STAA…

Staar Surgical (NSDQ:STAA) today said it has appointed Patrick Williams as chief financial officer, effective immediately.

Williams will report directly to the president and CEO Caren Mason. His appointment is part of a planned transition following Deborah Andrews’s retirement.

“STAAR is pleased to have a financial leader of Patrick’s caliber join the team at a time of such significant global opportunity for our EVO family of lenses,” Mason said in a news release. “Patrick has an impressive record of success in executive leadership roles in medical devices. His financial and operational experience in leading consumer-facing and marketing focused medical device companies makes him well suited to join STAAR. He has demonstrated a track record of success in significantly growing revenue and shareholder value.”

Williams has more than 20 years of experience in financial and operational management with public companies. He most re…